SRC and prostate cancer: Moreover, CSN5i-3, a novel selective and orally available CSN5 inhibitor, significantly inhibits SRC family signaling (such as SRC and YES), showing potential therapeutic effects in prostate cancer (Mazzu et al., 2022).